Want to see JP:4925 full AI Analyst Report?
Top Page
HABA Laboratories, Inc.
(4925)
Select Model
Select Model
Rating:67Neutral
Price Target:
¥1,830.00
▲(10.24% Upside)
Action:Reiterated
Date:05/16/26
The score is driven primarily by improving financial fundamentals (profitability turnaround and low leverage) and attractive valuation (low P/E with a dividend). These positives are partially offset by weak technicals (negative MACD and price below key moving averages), which indicates near-term market momentum remains unfavorable.
Positive Factors
High gross margins
Sustained gross margins near 65–71% indicate durable product-level economics and pricing power in skincare. High gross margins provide long-term room to absorb cost inflation, support marketing and R&D reinvestment, and underpin profitability even if top-line growth is only modest.
Negative Factors
Modest net margins
Despite strong gross margins, net margin near 6% leaves limited buffer for margin compression from rising SG&A or raw-material costs. Modest bottom-line margins constrain internal reinvestment capacity and mean profitability is more sensitive to adverse cost or demand shocks.
Read all positive and negative factors
Positive Factors
Negative Factors
High gross margins
Sustained gross margins near 65–71% indicate durable product-level economics and pricing power in skincare. High gross margins provide long-term room to absorb cost inflation, support marketing and R&D reinvestment, and underpin profitability even if top-line growth is only modest.
Read all positive factors
HABA Laboratories, Inc. (4925) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥6.46B
Dividend Yield2.38%
Average Volume (3M)2.14K
Price to Earnings (P/E)8.5
Beta (1Y)0.25
Revenue Growth0.66%
EPS Growth31.88%
CountryJP
Employees631
SectorConsumer Defensive
Sector Strength42
IndustryHousehold & Personal Products
Share Statistics
EPS (TTM)169.00
Shares Outstanding3,935,000
10 Day Avg. Volume2,940
30 Day Avg. Volume2,136
Financial Highlights & Ratios
PEG Ratio0.27
Price to Book (P/B)0.67
Price to Sales (P/S)0.53
P/FCF Ratio5.54
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
HABA Laboratories, Inc. Business Overview & Revenue Model
Company Description
Established in Tokyo, Japan, in 1983, HABA Laboratories, Inc. develops and distributes a comprehensive range of skincare, hair, and body care items both domestically and across international markets. Their skincare portfolio encompasses facial cle...
How the Company Makes Money
HABA Laboratories, Inc. generates revenue by manufacturing and selling a wide range of skincare and beauty products through multiple channels, including direct sales, retail stores, e-commerce platforms, and wholesale distribution. The company lik...
HABA Laboratories, Inc. Financial Statement Overview
Summary
Income Statement
62
Positive
Balance Sheet
78
Positive
Cash Flow
70
Positive
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 12.02B | 12.14B | 12.06B | 12.32B | 12.04B | 12.91B |
| Gross Profit | 8.08B | 7.95B | 7.99B | 8.03B | 8.17B | 8.79B |
| EBITDA | 976.87M | 898.40M | 811.56M | -1.31B | 17.05M | 448.30M |
| Net Income | 638.78M | 760.36M | 576.57M | -2.12B | -707.87M | -269.03M |
Balance Sheet | ||||||
| Total Assets | 11.76B | 12.52B | 12.34B | 12.43B | 14.73B | 15.76B |
| Cash, Cash Equivalents and Short-Term Investments | 4.48B | 5.78B | 4.74B | 3.96B | 4.82B | 5.65B |
| Total Debt | 1.56B | 1.19B | 1.82B | 2.36B | 2.03B | 2.56B |
| Total Liabilities | 2.95B | 3.04B | 3.42B | 3.92B | 3.96B | 4.12B |
| Stockholders Equity | 8.82B | 9.54B | 8.93B | 8.51B | 10.77B | 11.64B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 1.16B | 1.48B | -1.02B | -232.69M | 1.53B |
| Operating Cash Flow | 0.00 | 1.24B | 1.62B | -587.92M | 55.96M | 1.71B |
| Investing Cash Flow | 0.00 | 484.54M | -147.18M | -441.79M | -214.40M | -216.49M |
| Financing Cash Flow | 0.00 | -780.75M | -689.49M | 171.06M | -676.32M | -1.51B |
HABA Laboratories, Inc. Technical Analysis
Positive
1660.00
Price Trends
1704.16
Positive
1722.98
Negative
1690.35
Positive
Market Momentum
0.30
Negative
50.56
Neutral
63.33
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4925, the sentiment is Positive. The current price of 1660 is below the 20-day moving average (MA) of 1705.60, below the 50-day MA of 1704.16, and below the 200-day MA of 1690.35, indicating a bullish trend. The MACD of 0.30 indicates Negative momentum. The RSI at 50.56 is Neutral, neither overbought nor oversold. The STOCH value of 63.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4925.
HABA Laboratories, Inc. Peers Comparison
UnderperformOutperform
Sector (62)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | ¥1.64B | 11.46 | ― | ― | -9.84% | ― | |
67 Neutral | ¥6.46B | 8.49 | ― | 2.38% | 0.66% | 31.88% | |
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
61 Neutral | ¥5.22B | 24.35 | ― | 1.68% | 4.84% | 57.41% | |
59 Neutral | ¥2.40B | 7.07 | ― | 1.72% | -5.61% | 57.31% | |
58 Neutral | ¥7.98B | 44.07 | ― | 2.65% | 0.96% | -28.27% | |
56 Neutral | ¥20.62B | 10.73 | ― | 0.91% | 7.04% | -34.37% |
* Consumer Defensive Sector Average
JP:4925
HABA Laboratories, Inc.
1,707.00
80.96
4.98%
JP:4918
Ivy Cosmetics Corporation
289.00
-27.89
-8.80%
JP:4920
Nippon Shikizai, Inc.
1,145.00
117.95
11.48%
JP:4926
C'BON COSMETICS Co., Ltd.
1,220.00
111.58
10.07%
JP:4933
I-ne CO., LTD.
1,159.00
-413.65
-26.30%
JP:4936
AXXZIA, Inc.
331.00
-135.08
-28.98%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.